Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Deregulation Likely to Create 1.15 Trillion Yen Headroom for Switched OTC Growth: Health Economist
July 15, 2022
- Gynecologist Cautious about Inclusion of Pregnant Women in Clinical Trials, but Says ICH Move Will Spark Safety Discussions
July 14, 2022
- NCC Doctor Hails MHLW’s Policy on Use of Clinical Research Data in Regulatory Filing
June 22, 2022
- Kitasato University Spinoff PRD to Develop Lipid Metabolism Control Agents
June 10, 2022
- NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
- A Dozen Regional Formularies to Be Launched by Year-End, Pharmacists Must Take the Lead: Society Chief
May 25, 2022
- Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
May 9, 2022
- 5 Academic Societies Prod Price Rethink for 32 Key Antibiotics to Stabilize Supply
May 9, 2022
- Insurance Coverage of Fertility Treatments Could Reduce Patients’ Payments by 20-30%: Obstetrician
April 11, 2022
- Ex-JAMS President Fumimaro Takaku Dies at 91
March 28, 2022
- Exon 44-Targeted DMD Drug Hits Goals in PI/II: NCNP/Nippon Shinyaku
March 18, 2022
- Japan Researchers Test Efficacy of COVID Drugs for BA.2 Omicron Subvariant
March 11, 2022
- Infectious Diseases Society Issues Updated COVID-19 Guide
February 21, 2022
- COVID-19 Vaccines for Ages 5 to 11 Meaningful: Japan Pediatric Society
January 20, 2022
- Oita University Completes Dosing of Replicon RNA Vaccine in PI, Eyes Global PII/III
January 19, 2022
- Kyoto Univ., Takeda Succeed in Treating Muscular Dystrophy in Model Mice Using Genome Editing
December 10, 2021
- With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
- Swift Actions to Improve Diagnostic System, Control Costs Required to Prep for Potential Aducanumab Debut: JSDR Confab
November 30, 2021
- Anti-CGRP Antibodies Cut Headaches in 70% of Patients, but Cost Will Be Major Obstacle: Specialist
October 21, 2021
- Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…